Pseudobulbar Affect

Abstract

Pseudobulbar affect (PBA) is a neurological disorder of emotional expression in which brief, involuntary outbursts of laughing or crying erupt without a matching feeling and out of proportion to any trigger. It follows injury to the brain networks that regulate emotional motor output — in stroke, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, and neurodegenerative disease — and is distinct from the mood disorders with which it is confused. First described by Kinnier Wilson in 1924 and reframed by modern imaging as a disorder of a corticopontine-cerebellar circuit, PBA is common, treatable, and under-recognised. This article traces its clinical picture, its separation from depression, its mechanism, its measurement with the CNS-LS scale, and its treatment. Three interactive demonstrations let a reader distinguish PBA from a mood disorder, disinhibit the emotional-motor circuit, and score the screening scale.

Keywords: pseudobulbar affect, pathological laughing and crying, emotional lability, involuntary emotional expression disorder, dextromethorphan-quinidine

Pseudobulbar affect is a disorder of the expression of emotion, not of emotion itself. According to MeSH, which classifies it among the neurologic manifestations of disease, it is a neurological condition in which the motor acts of laughing and crying are released from their normal control, so that they occur suddenly, involuntarily, and without the inner feeling they usually signal. A person with PBA may weep uncontrollably at a mildly sad remark, or laugh at a solemn moment, while reporting little or no corresponding sadness or mirth; the outburst is stereotyped, brief, and difficult to suppress, and it frequently mismatches the situation that triggered it. Because the outward display of emotion is what observers read, PBA is easily mistaken for depression, mania, or a personality change, and this confusion is the central clinical problem the disorder poses (Cummings et al., 2006). It is common wherever the brain's emotional-motor pathways are damaged, and it responds to treatment, yet it remains widely unrecognised and untreated (Work et al., 2011).

The Historic Account and Its Modern Reinterpretation

The clinical picture was fixed in the language of neurology by Samuel Alexander Kinnier Wilson, whose 1924 paper on the problems of laughing and crying gave the disorder its enduring description and its mechanism in outline. Wilson set out the paradox that defines the condition: patients who laughed or wept helplessly, in paroxysms they could not command, while denying the feeling the display announced. He argued that the acts of laughing and crying are organised by a centre in the brainstem, and that this centre is normally held in check by descending pathways from the cerebral cortex; when disease severs that control, the brainstem apparatus is released and fires on slight provocation (Wilson, 1924). This release model — a lower motor programme freed from higher inhibition — became the standard account and still frames the textbook explanation of the disorder.

The founding anatomy was refined rather than overturned by later work, and its refinement moved the cerebellum from the periphery of the story to its centre. Josef Parvizi, Antonio Damasio, and colleagues re-examined the release theory and proposed that the cerebellum does not merely permit the outburst but modulates it, adjusting the expression of emotion to the cognitive and situational context; on their account PBA is a disorder in which the cerebellar circuits that should calibrate emotional display to context are disconnected from the information that would keep the display appropriate (Parvizi et al., 2001). The refinement matters because it explains the incongruity that a simple release model does not: the problem is not only that laughing and crying escape control but that they are no longer matched to the moment, which is exactly what a lost calibrating signal would produce (Parvizi et al., 2009).

The Clinical Picture

The presenting feature of PBA is a sudden, involuntary episode of laughing or crying, and its diagnostic weight lies in a set of qualities that separate it from an ordinary emotional response. The episodes are paroxysmal — they begin abruptly, run a brief and stereotyped course, and end as sharply as they started — and they are difficult or impossible to suppress once underway. Crucially, they are often mood-incongruent: a patient may cry without sadness or laugh without mirth, and the same trivial cue may set off the same outburst each time. The older clinical literature captured this with the term emotional incontinence, and the broader syndrome, which spans both laughing and crying, is called pathological laughing and crying (Wortzel et al., 2008). A consensus effort proposed involuntary emotional expression disorder as an umbrella label meant to cover the whole spectrum from strictly mood-incongruent outbursts to exaggerated but congruent ones (Cummings et al., 2006).

The clinically decisive task is to tell PBA apart from a primary mood disorder, because the crying of PBA is routinely misread as depression and treated, or dismissed, on that basis (Miller et al., 2011). The two differ on features a careful history can probe: the trigger, the relation to sustained mood, the duration of the episode, the degree of control, the mood between episodes, and the reported inner feeling. Table 1 sets the discriminating features side by side, and the first demonstration lets a reader toggle those features of a single crying episode and watch the classification shift between pseudobulbar affect and a depressive episode, making explicit which features actually carry the distinction.

Mechanism: The Emotional-Motor Circuit

The mechanism of PBA is best understood as a failure of control in a distributed circuit rather than damage to a single centre. The motor programmes for laughing and crying are organised in the brainstem, and in the intact brain they are governed by descending signals: the corticobulbar tract carries voluntary and inhibitory control from the motor cortex to the brainstem nuclei, while a wider corticopontine-cerebellar circuit supplies the contextual regulation that keeps emotional display proportionate and appropriate (Parvizi et al., 2001). When disease interrupts these descending pathways — the classic case being bilateral damage that produces pseudobulbar palsy, of which the affective disturbance is one component — the brainstem apparatus loses its governor, and emotional expression becomes disinhibited, easily triggered, and detached from the situation (King & Reiss, 2013).

Two features of the circuit account for the disorder's signature. First, because the lost signal is regulatory rather than generative, the emotion machinery still works — indeed it works too readily — which is why the display can be intense while the underlying feeling is muted or absent. Second, because the cerebellum contributes the calibration of display to context, its disconnection produces incongruity specifically: expression that is not merely excessive but mismatched to the moment (Parvizi et al., 2009). This network view also explains the disorder's aetiological breadth: any condition that damages enough of the descending and cerebellar pathways can release the same final behaviour, which is why PBA appears across such varied diseases and why its severity tracks the burden of pathway damage rather than any one lesion site. The second demonstration renders this circuit as an adjustable model: a reader lowers the descending inhibitory control and the cerebellar calibrating signal and watches the brainstem output shift from proportionate, congruent expression to the disinhibited, incongruent outbursts of PBA.

Figure 1

The Dissociation of Expression from Experience in Pseudobulbar Affect

Prevalence and the Diseases It Accompanies

PBA is not a rare curiosity but a common accompaniment of neurological disease, and its frequency is one argument for looking for it deliberately. Estimates vary with the population and the threshold used, but surveys across the major neurological conditions — stroke, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson disease, Alzheimer disease, and others — place the number of affected patients in the United States alone in the range of roughly one to two million, with prevalence within any given disease commonly reported in the tens of percent (Work et al., 2011; Colamonico et al., 2012). A systematic review and meta-analysis of PBA after stroke, for instance, found the disorder in a substantial minority of survivors, confirming that a familiar disease carries a frequently missed complication (Gillespie et al., 2016).

The burden of the disorder is not confined to the episodes themselves. Because the outbursts are public, unpredictable, and easily misread, they carry social and occupational costs out of proportion to their duration: patients restrict activities, withdraw from company, and are misjudged by others who read the display as the emotion it imitates (Colamonico et al., 2012). Amyotrophic lateral sclerosis is an instructive case, because the same disease that weakens the bulbar muscles also frequently produces PBA, so a patient may be doubly burdened — impaired in the voluntary control of the face and voice and subject to involuntary emotional displays through the same failing system (Ahmed & Simmons, 2013). Recognising the disorder is therefore not a diagnostic nicety but a step with direct consequences for how a patient is understood and treated.

Measurement: Screening and Its Limits

Because PBA is defined by the quality of emotional episodes rather than by a lesion or a laboratory value, its measurement rests on structured clinical report, and the most widely used instrument is the seven-item Center for Neurologic Study–Lability Scale (CNS-LS). Each item asks how often a patient experiences a facet of the disorder — outbursts that do not match the feeling, laughing or crying that cannot be stopped, displays triggered by trivial cues — and is rated from 1 to 5, so the total ranges from 7 to 35; a score at or above a conventional cutoff flags probable PBA and prompts fuller assessment (Sauve, 2016). The scale is quick, validated, and useful precisely because the disorder is otherwise easy to overlook, and it has been adopted both in clinics and as an entry criterion in treatment trials (Ahmed & Simmons, 2013).

A screening score is not a diagnosis, and the reason is a general property of screening that the worked example below makes concrete. Any threshold on a scale trades false positives against false negatives, and the chance that a positive screen reflects true PBA — its positive predictive value — depends not only on the scale's accuracy but on how common the disorder is in the setting where it is applied. In a population where PBA is uncommon, even an accurate scale returns many false positives, so a positive CNS-LS must be confirmed against the clinical picture in Table 1 rather than taken as sufficient on its own (Miller et al., 2011). The third demonstration presents the seven CNS-LS items as adjustable responses, tallies the score against the cutoff in real time, and shows how the same total means different things depending on the base rate of the disorder in the clinic.

Worked Example

Consider a patient screened with the CNS-LS. The seven items receive ratings of 4, 3, 5, 2, 4, 3, and 4, which sum to 25. Because 25 exceeds the conventional cutoff of 13, the screen is positive, and a naive reading would treat that as establishing the diagnosis. The screen alone does not, and seeing why requires one more step.

Suppose the scale, at this cutoff, detects four in five true cases (sensitivity 0.80) and correctly clears four in five people without the disorder (specificity 0.80), and suppose it is applied in a general clinic where PBA is present in 10% of patients. Of 1,000 patients, 100 have PBA and 900 do not. The scale flags 0.80 × 100 = 80 of the true cases and 0.20 × 900 = 180 of the unaffected — a false alarm on one in five of the 900. A positive screen therefore identifies 80 + 180 = 260 patients, of whom only 80 truly have PBA, so the positive predictive value is 80 / 260 = 0.31. Even with a reasonably accurate scale, fewer than a third of positive screens in this setting are true cases, because the disorder's low base rate lets the many unaffected patients dominate the false positives. Raise the base rate — screen instead in an ALS or multiple-sclerosis clinic where PBA is common — and the same score becomes far more likely to be a true positive; the number on the scale has not changed, but what it warrants has. The lesson is the one the demonstration illustrates: a CNS-LS score is a reason to look harder, not a diagnosis, and its meaning is fixed only when the clinical picture and the setting are supplied.

Treatment

PBA is treatable, which is the practical reason that recognising it matters. The best-established therapy is a fixed combination of dextromethorphan with a low dose of quinidine, an approach whose logic is pharmacological: dextromethorphan acts within the brain — notably at the sigma-1 receptor and on glutamatergic transmission — to dampen the disinhibited emotional-motor output, but it is normally metabolised too quickly to reach useful levels, so a subtherapeutic dose of quinidine is added to block that metabolism and raise dextromethorphan's concentration (Schiffer & Pope, 2005). A randomised trial established the combination's efficacy in PBA arising from amyotrophic lateral sclerosis, showing reduced episode frequency against placebo (Pioro et al., 2010), and later open-label work extended the evidence to PBA following traumatic brain injury and stroke (Hammond et al., 2018).

Dextromethorphan-quinidine is not the only option, and the choice depends on the setting and the cause. Antidepressants — tricyclics and selective serotonin reuptake inhibitors — have long been used and can reduce the frequency and severity of episodes, often at lower doses and with a faster effect than in the treatment of depression, which is itself a clue that the target is not a mood disorder (Wortzel et al., 2008). The evidence base is strongest for emotionalism after stroke, where controlled trials of antidepressants have shown benefit (Hackett et al., 2010). Across causes, the common thread is that a disorder routinely missed or misattributed to depression has specific, effective treatments, so the clinical value of distinguishing it — the theme of this article — is not academic (Sauve, 2016).

Discussion

Pseudobulbar affect occupies an instructive place in the science of emotion because it dissociates the expression of emotion from the experience of it. In everyday life the two run together so tightly that we treat a face in tears as evidence of sadness; PBA breaks the link, producing the display without the feeling, and in doing so it shows that emotional expression is a controllable motor output governed by its own dedicated circuitry rather than an automatic read-out of an inner state (Parvizi et al., 2001). The disorder thus supports a componential view of emotion, in which generation, regulation, and expression are separable systems that disease can pull apart, much as the classical aphasias separated the components of language.

The disorder is also a standing lesson in the cost of misdiagnosis. Its resemblance to depression is not superficial — both can present with frequent crying — and the resemblance has real consequences when the pseudobulbar crying is treated as a mood disorder or, worse, dismissed as emotional weakness (Miller et al., 2011). The corrective is the same combination that runs through the whole topic: a mechanistic account that locates the fault in a motor-control circuit, a set of clinical features that distinguish incongruent, paroxysmal outbursts from sustained low mood, a screening tool whose limits are understood, and specific treatments that follow from getting the diagnosis right (Cummings et al., 2006; King & Reiss, 2013). PBA remains under-recognised, and the gap between how common and how treatable it is, on the one hand, and how often it is missed, on the other, is the practical problem the field continues to address (Work et al., 2011).

Current Directions

Recent work has been less concerned with redefining PBA than with widening the evidence for its treatment and sharpening its recognition across the diseases that produce it. The pivotal dextromethorphan-quinidine trials were conducted in amyotrophic lateral sclerosis and multiple sclerosis, and a continuing line of open-label and observational studies has extended the safety and effectiveness data to other causes, including traumatic brain injury and dementia, so that the treatment's evidence base now spans a broader range of the conditions in which the disorder actually occurs (Hammond et al., 2018). Alongside the trial literature, detailed case reports document the management of PBA in complex, mixed neurodegenerative presentations and probe practical questions of dosing and formulation that the registration trials did not settle (Villeneuve et al., 2020). A parallel strand continues to press the epidemiology — quantifying how often PBA accompanies specific diseases such as stroke through systematic review and meta-analysis, which turns clinical impression into a measured prevalence and strengthens the case for routine screening (Gillespie et al., 2016). Running through this work is a shift in emphasis from establishing that PBA exists and can be treated to ensuring it is found and treated in the settings where it is most common (Sauve, 2016).

Common Misconceptions

Pseudobulbar affect is a form of depression.

It is a neurological disorder of emotional expression, not a mood disorder. The episodes are brief and stereotyped, the mood between them is normal, and the display need not match any sustained feeling, so treating it as depression misses both the mechanism and the specific therapies (Cummings et al., 2006; Miller et al., 2011).

The laughing or crying reflects the patient's true feeling.

The defining feature is that the display is often incongruent with, or wildly out of proportion to, the inner state; a patient may weep without sadness because the fault is in the motor control of expression, not in the emotion it usually signals (Parvizi et al., 2001).

A high screening score confirms the diagnosis.

The CNS-LS screens; it does not diagnose. Its positive predictive value depends on how common PBA is in the setting, so a positive score must be confirmed against the clinical picture rather than taken as sufficient on its own (Sauve, 2016).

Glossary

Affective lability.

Rapid, poorly controlled shifts in the outward display of emotion; the broad category of which pseudobulbar affect is the disorder marked by frank incongruity.

Amyotrophic lateral sclerosis.

A progressive degeneration of motor neurons; a common setting for pseudobulbar affect and the population in which its leading treatment was first tested.

Cerebellum.

The hindbrain structure that, on the modern account, calibrates emotional display to context; its disconnection produces the incongruity of pseudobulbar affect.

CNS-LS.

The Center for Neurologic Study–Lability Scale, a seven-item self-report screen for pseudobulbar affect scored from 7 to 35 against a cutoff.

Corticobulbar tract.

The pathway carrying voluntary and inhibitory control from the motor cortex to the brainstem nuclei of the face and voice; its interruption releases the emotional-motor programmes.

Corticopontine-cerebellar circuit.

The distributed loop through which the cortex, pons, and cerebellum regulate emotional expression; its disruption is the network account of pseudobulbar affect.

Dextromethorphan.

A centrally acting agent, active at the sigma-1 receptor and on glutamatergic transmission, that dampens the disinhibited output of pseudobulbar affect.

Emotional incontinence.

An older clinical term for the involuntary, poorly suppressed laughing or crying of pseudobulbar affect.

Involuntary emotional expression disorder.

A proposed umbrella label for the spectrum of disorders of emotional display, from strictly incongruent outbursts to exaggerated but congruent ones.

Mood-congruent.

Matching the underlying feeling; pseudobulbar episodes are often mood-incongruent, which is what distinguishes them from a depressive display.

Pathological laughing and crying.

The classical name for the full syndrome spanning both involuntary laughing and involuntary crying; largely synonymous with pseudobulbar affect.

Positive predictive value.

The probability that a positive screen reflects the true condition; it depends on the base rate, which is why a positive CNS-LS means more in a high-prevalence clinic.

Pseudobulbar palsy.

The syndrome of bilateral corticobulbar damage, of which pseudobulbar affect is the emotional-expression component alongside difficulties of speech and swallowing.

Quinidine.

A metabolic inhibitor added at low dose to raise the brain concentration of dextromethorphan, enabling the combination treatment for pseudobulbar affect.

Sigma-1 receptor.

A neuronal receptor at which dextromethorphan acts, part of the pharmacological rationale for its use in pseudobulbar affect.

Key Researchers

David B. Arciniegas (contemporary). Behavioral neurologist and neuropsychiatrist at Baylor College of Medicine; he contributed to the consensus framework for involuntary emotional expression disorder and to reviews of the epidemiology and treatment of pathological laughing and crying. Faculty Page - Google Scholar

Benjamin Rix Brooks (contemporary). Neurologist at the Atrium Health Neurosciences Institute; a principal investigator on the dextromethorphan-quinidine trials that established an evidence-based treatment for pseudobulbar affect in ALS and multiple sclerosis. ORCID - Google Scholar

Jeffrey L. Cummings (contemporary). Neurologist at the University of Nevada, Las Vegas; he led the consensus effort that proposed involuntary emotional expression disorder as an umbrella definition for the spectrum of disordered emotional display. Faculty Page - Google Scholar

Antonio R. Damasio (contemporary). Neuroscientist at the University of Southern California; with Josef Parvizi he advanced the cerebellar-network account of pathological laughing and crying, reframing the disorder as a failure to calibrate emotional expression to context. Wikipedia - Wikidata

Josef Parvizi (contemporary). Neurologist at Stanford University; his work on the neuroanatomy of pathological laughing and crying refined the classical release theory into a model in which the cerebellum modulates emotional display. Faculty Page - ORCID - Google Scholar

Erik P. Pioro (contemporary). Neurologist and ALS clinician-scientist at the University of British Columbia; he led the STAR trial of dextromethorphan-quinidine that demonstrated its efficacy against pseudobulbar affect. ORCID - Google Scholar

Samuel Alexander Kinnier Wilson (1878-1937). British neurologist at Queen Square, London; his 1924 paper gave the classic description of pathological laughing and crying and framed it as a release of brainstem emotional programmes from cortical control. Wikipedia - Wikidata

Frequently Asked Questions

What is pseudobulbar affect?
It is a neurological disorder of emotional expression in which brief, involuntary episodes of laughing or crying occur suddenly, are hard to control, and are often out of proportion to, or incongruent with, the person's actual feeling (Cummings et al., 2006).

How is it different from depression?
The episodes of PBA are sudden and brief, the mood between them is normal, and the display need not match any sustained feeling, whereas depression is a persistent low mood; the crying of PBA is a motor-control problem, not a mood disorder (Miller et al., 2011).

What causes pseudobulbar affect?
It arises when disease disrupts the corticobulbar and corticopontine-cerebellar pathways that regulate emotional motor output, releasing the brainstem programmes for laughing and crying from their normal control (Parvizi et al., 2001; King & Reiss, 2013).

Which conditions is it associated with?
PBA accompanies many neurological diseases, including stroke, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson disease, and dementia, affecting an estimated one to two million people in the United States (Work et al., 2011; Colamonico et al., 2012).

How is it diagnosed?
It is a clinical diagnosis based on the character of the episodes; the seven-item CNS-LS scale is a validated screen, but a positive score must be confirmed against the clinical picture because its predictive value depends on how common PBA is in the setting (Sauve, 2016).

Can pseudobulbar affect be treated?
Yes. A combination of dextromethorphan and low-dose quinidine is an evidence-based treatment shown effective in randomised trials, and antidepressants are also used to reduce the frequency and severity of episodes (Pioro et al., 2010; Wortzel et al., 2008).

Why is it so often missed?
Because the outward display imitates the emotion it usually signals, PBA is routinely misread as depression, mania, or a personality change, and it remains widely unrecognised despite being common and treatable (Work et al., 2011).

Does the person feel the emotion they display?
Often not, or not to the degree shown; the defining feature is that the expression is exaggerated or incongruent relative to the inner state, because the disorder affects the motor expression of emotion rather than the emotion itself (Parvizi et al., 2009).

References